Cryogen-Free dissolution Dynamic Nuclear Polarization polarizer operating at 3.35 T, 6.70 T and 10.1 T

Purpose: A novel dissolution dynamic nuclear polarization (dDNP) polarizer platform is presented. The polarizer meets a number of key requirements for in vitro, pre-clinical and clinical applications. Method: It uses no liquid cryogens, operates in continuous mode, accommodates a wide range of sample sizes up to and including those required for human studies, and is fully automated. Results: It offers a wide operational window both in terms of magnetic field, up to 10.1 T, and temperature, from room temperature down to 1.3 K. The polarizer delivers a 13C liquid state polarization for [1-13C]pyruvate of 70%. The build-up time constant in the solid state is approx. 1200 s (20 min), allowing a sample throughput of at least one sample per hour including sample loading and dissolution. Conclusion: We confirm the previously reported strong field dependence in the range 3.35 to 6.7 T, but see no further increase in polarization when increasing the magnetic field strength to 10.1 T for [1-13C]pyruvate and trityl. Using a custom dry magnet, cold head and recondensing, closed-cycle cooling system, combined with a modular DNP probe, automation and fluid handling systems; we have designed a unique dDNP system with unrivalled flexibility and performance.Comment: 16 pages, 8 figure

<i>In Vivo</i> phenotyping of tumor metabolism in a canine cancer patient with simultaneous ¹⁸F-FDG-PET and hyperpolarized ¹³C-Pyruvate magnetic resonance spectroscopic imaging (hyperPET):mismatch demonstrates that FDG may not always reflect the Warburg effect

In this communication the mismatch between simultaneous 18F-FDG-PET and a 13C-lactate imaging (hyperPET) in a biopsy verified squamous cell carcinoma in the right tonsil of a canine cancer patient is shown. The results demonstrate that 18F-FDG-PET may not always reflect the Warburg effect in all tumors

Detection of 3D Cardiac metabolism after injection of hyperpolarized [1-13C]pyruvate

Introduction MRI with hyperpolarised 13C represents a promising modality for in-vivo spectroscopy and provides a unique opportunity for non-invasive assessment of cardiac regional metabolism. Purpose We present a method based on a volumetric IDEAL spiral CSI acquisition for obtaining spatial information on the metabolism of the whole heart after intravenous injection of hyperpolarized [1-13C]pyruvate in a large animal model with a clinical 3T scanner. Methods Three healthy male mini-pigs (38±2 kg) were maintained under deep sedation; a dose of 20 mL of 230 mM [1-13C]pyruvate was administered over about 10 s by manual injection. Animal experiments were performed on a 3T GE Signa HDx scanner with a 13C quadrature birdcage coil. [1-13C]pyruvate was polarized using a HyperSense DNP polariser with subsequent dissolution. The final injection solution contained 230 mM sodium [1-13C]pyruvate, 100 mM TRIS buffer, 0.27 mM Na2EDTA and 20 μM Dotarem with T≈37°C and pH ≈ 7.6. Anatomical reference images were acquired in the axial plane with standard FIESTA sequence (body coil FOV=30x30 cm2, FA=20°, TE/TR=3.8ms/7.52ms, matrix 224x160, slice thickness 5 mm, 20 slices). Metabolic information covering the heart were obtained using a 3D IDEAL spiral CSI prescribed on the same region imaged by the reference anatomical sequence (FOV= 30x30 cm, slab thickness=100mm) starting 20 seconds after the beginning of the hyperpolarized [113C]-pyruvate injection. The IDEAL spiral CSI concept was implemented into a multi-slice, pulse-and-acquire sequence with a 2D spiral readout and phase encoding along the third dimension. A constant echo time shift of TE=0.9ms, 11 encoding steps and FA=7° were used to optimize the study for the considered frequencies. The data was reconstructed using spectrally-preconditioned, minimum-norm CS inversion followed by gridding reconstruction implemented in Matlab. The reconstruction on cardiac short axis (SA) and image fusion was performed by PMOD software. Results Pyruvate and its metabolic products lactate and bicarbonate were detected in the heart. Metabolic maps overlaid on anatomical images are shown in Figure 1. On SA sections the metabolites signal resulted correctly localized in cardiac structures: pyruvate more evident in ventricular cavity, bicarbonate in myocardial wall

Imaging of Glucose Metabolism by 13C-MRI Distinguishes Pancreatic Cancer Subtypes in Mice

Metabolic differences among and within tumors can be an important determinant in cancer treatment outcome. However, methods for determining these differences non-invasively in vivo is lacking. Using pancreatic ductal adenocarcinoma as a model, we demonstrate that tumor xenografts with a similar genetic background can be distinguished by their differing rates of the metabolism of 13C labeled glucose tracers, which can be imaged without hyperpolarization by using newly developed techniques for noise suppression. Using this method, cancer subtypes that appeared to have similar metabolic profiles based on steady state metabolic measurement can be distinguished from each other. The metabolic maps from 13C-glucose imaging localized lactate production and overall glucose metabolism to different regions of some tumors. Such tumor heterogeneity would not be not detectable in FDG-PET